Abstract
Mycobacterial fatty acid synthase type-I (FAS-I) has an important role in the de novo synthesis of fatty acids, which constitute a major component of the cell wall. The essentiality of FAS-I in the survival and growth of mycobacterium makes it an attractive drug target. However, targeted inhibitors against Mycobacterial FAS-I have not been reported yet. Recently, the structure of FAS-I from Mycobacterium tuberculosis was solved. Therefore, in a quest to find potential inhibitors against FAS-I, molecular docking-based virtual screening and molecular dynamics simulation were done. Subsequently, molecular dynamic simulations based on binding free energy calculations were done to gain insight into the predicted binding mode of putative hits. The detailed analysis resulted in the selection of four putative inhibitors. For compounds BTB14738, RH00608, SPB02705, and CD01000, binding free energy was calculated as −72.27 ± 12.63, −68.06 ± 11.80, −63.57 ± 12.22, and −51.28 ± 13.74 KJ/mol, respectively. These compounds are proposed to be promising pioneer hits.
Highlights
Tuberculosis (TB) is a leading health problem worldwide
The pyrazinamide analogs have been reported as competitive inhibitors of fatty acid synthase type-I (FAS-I) for NADPH binding
In pursuit of finding potential inhibitors against FAS-I, we carried out structure-based virtual screening, focusing on the NADPH
Summary
Tuberculosis (TB) is a leading health problem worldwide. According to the WorldHealth Organization estimation, 10 million new cases were reported in 2018 alone, and1.5 million people have died of it [1]. Tuberculosis (TB) is a leading health problem worldwide. Health Organization estimation, 10 million new cases were reported in 2018 alone, and. 1.5 million people have died of it [1]. Tuberculosis is contagious and an airborne disease caused by Mycobacterium tuberculosis. The current drug regimen for the treatment of TB relies upon a six-month course of anti-microbial drugs [2]. The lengthy regimen leads to non-adherence and the emergence and spread of drug-resistant strains. The rise of multi drug-resistant strains and co-occurrence with HIV pose challenges in combating mycobacterium [2]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.